News & Media

NEW YORK, October 30, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the addition of 33 new customer accounts during its fiscal first quarter for the period ended September 30, 2025, representing a 50% increase compared with the same…

NEW YORK, October 23, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has secured a major new contract with one of the United Kingdom’s largest industrial service providers.  The multinational company, a global leader operating across the energy,…

The Workplace Health & Safety Show (WHS Show) returns to Sydney this October as the flagship event in Australia’s leading series dedicated to workplace health and safety. Held during National Safe Work Month, the WHS Show Sydney draws together over 6,000 professionals and 200+ exhibitors for two days of knowledge-sharing, networking, and innovation. Drug use in the…

Time: 4PM AEDT | 9AM GST | 2PM JST | 10:30AM IST Discover a faster, non-invasive, and more efficient approach to workplace drug testing. See firsthand how fingerprint drug testing streamlines sample collection, reduces labor, and improves compliance. Explore the limitations and challenges of traditional workplace drug testing methods, including urine and saliva. See how…

NEW YORK, September 26, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today is providing an update on the timeline for anticipated FDA 510(k) clearance for the use of its Intelligent Fingerprinting Drug Screening System for the opiate codeine.    Following recent…

In December 2024, INBS submitted its 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for review and clearance of its Intelligent Fingerprinting Drug Screening System. As expected, the FDA reviewed and responded with questions by issuing an Additional Information (AI) request in February 2025. This AI request consisted of over 70 items to be addressed by the Company. With the support of specialized FDA consultants and expert third-party partners, INBS responded to the FDA’s questions and submitted additional information in August 2025

NEW YORK, August 06, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the submission of its Additional Information (“AI”) response to the United States Food and Drug Administration (“FDA”) as part of its ongoing 510(k) clearance process for planned entry to…

NEW YORK, July 30, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has secured a major contract with one of London’s largest public transport operators, spanning 14 operational sites in greater London and employing over 4,400 staff. INBS’s…